CA2671904C - Intermediate duration neuromuscular blocking agents and antagonists thereof - Google Patents

Intermediate duration neuromuscular blocking agents and antagonists thereof Download PDF

Info

Publication number
CA2671904C
CA2671904C CA2671904A CA2671904A CA2671904C CA 2671904 C CA2671904 C CA 2671904C CA 2671904 A CA2671904 A CA 2671904A CA 2671904 A CA2671904 A CA 2671904A CA 2671904 C CA2671904 C CA 2671904C
Authority
CA
Canada
Prior art keywords
neuromuscular
cysteine
blocking agent
antagonist
neuromuscular blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2671904A
Other languages
English (en)
French (fr)
Other versions
CA2671904A1 (en
Inventor
John J. Savarese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of CA2671904A1 publication Critical patent/CA2671904A1/en
Application granted granted Critical
Publication of CA2671904C publication Critical patent/CA2671904C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2671904A 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof Active CA2671904C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87313206P 2006-12-06 2006-12-06
US60/873,132 2006-12-06
PCT/US2007/024914 WO2008070121A1 (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Publications (2)

Publication Number Publication Date
CA2671904A1 CA2671904A1 (en) 2008-06-12
CA2671904C true CA2671904C (en) 2012-07-03

Family

ID=39492558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2671904A Active CA2671904C (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Country Status (8)

Country Link
US (1) US8148398B2 (OSRAM)
EP (1) EP2101772B1 (OSRAM)
JP (1) JP5213137B2 (OSRAM)
CN (1) CN101588803B (OSRAM)
AT (1) ATE554769T1 (OSRAM)
AU (1) AU2007328210B2 (OSRAM)
CA (1) CA2671904C (OSRAM)
WO (1) WO2008070121A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007328210B2 (en) 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
BRPI0808272A2 (pt) * 2007-03-08 2014-07-08 Chemagis Ltd "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio"
EP2125743A1 (en) * 2007-03-26 2009-12-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
WO2008132748A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
AU2008273724B2 (en) * 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
WO2008155752A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
BRPI0812625A2 (pt) * 2007-07-09 2019-02-19 Chemagis Ltd processo para preparar um sal de cis-atracúrio
CA2702535A1 (en) * 2007-10-29 2009-05-07 Chemagis Ltd. Novel r,r'-atracurium salts
BRPI0907656A2 (pt) * 2008-05-01 2019-08-27 Chemagis Ltd composto para testar a pureza de cisatracúrio, método para testar a pureza de uma amostra de besilato de cisatracúrio, uso de um composto para testar a pureza de cisatracúrio e processo para preparar compostos para testar a pureza de cisatracúrio
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
US9156826B2 (en) 2012-06-29 2015-10-13 Cornell University Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN110776481B (zh) 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN108727248B (zh) 2018-07-25 2021-05-25 四川大学华西医院 一类双季铵化合物及其制备方法和用途
WO2021115413A1 (zh) * 2019-12-11 2021-06-17 江苏恒瑞医药股份有限公司 神经肌肉阻滞剂及其制备方法
JP7748737B2 (ja) * 2020-10-17 2025-10-03 コーネル・ユニバーシティー Ｎｍｂａ投与後の回復を制御および予測するための方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
US4036959A (en) * 1974-10-29 1977-07-19 Millmaster Onyx Corporation Microbiocidal capped polymers
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
US4039682A (en) * 1976-03-29 1977-08-02 Baxter Travenol Laboratories, Inc. Method and composition for relief of back pain
MC1197A1 (fr) * 1977-08-01 1979-03-19 Massachusetts Gen Hospital Composes tetrahydro-isoquinoleiniques myorelaxants(agents de blocage de la plaque neuro-musculaire)et leur preparation
US4192877A (en) * 1977-08-01 1980-03-11 Massachusetts General Hospital Neuromuscular blocking agents
US4235906A (en) * 1978-07-21 1980-11-25 Massachusetts General Hospital Bis-isoquinolinium compounds, compositions and methods of use
ATE921T1 (de) 1978-09-05 1982-05-15 Akzo N.V. Saeureadditionssalze von 2-beta, 16-beta-bis-piperidino-an drostan-16-beta-monoquaternaeren ammoniumderivaten und diese enthaltende pharmazeutische zusammensetzungen.
US4491665A (en) * 1979-10-19 1985-01-01 Burroughs Wellcome Co. Method of preparing isomers of bis isoquinolinium compounds
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
GR79603B (OSRAM) * 1982-07-24 1984-10-31 Pfizer
BG38182A1 (en) * 1983-06-21 1985-11-15 Ivanova Tocolytic means
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
DE3436179A1 (de) * 1984-10-03 1986-04-10 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung optisch aktiver amine
GB8518634D0 (en) * 1985-07-23 1985-08-29 Smithkline Beckman Corp Chemical compounds
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE4135710A1 (de) * 1991-10-30 1993-05-06 Basf Ag, 6700 Ludwigshafen, De Cyclische ammoniumverbindungen und ihre verwendung als glanzmittel fuer waessrig-saure galvanische nickelbaeder
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
US5739170A (en) * 1992-09-11 1998-04-14 The Regents Of The University Of California Inhibitors of metazoan parasite proteases
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
EP1526130A1 (en) 1997-03-25 2005-04-27 Avera Pharmaceuticals, Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers
WO1998047534A1 (de) * 1997-04-18 1998-10-29 Klinge Pharma Gmbh Stabilisiertes arzneimittel enthaltend cysteinylderivate
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
ATE367145T1 (de) * 1999-12-21 2007-08-15 Kao Corp Topische kosmetische und pharmazeutische mittel enthaltend spezifische alkoxilierte diester der fumarsäure
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US7763263B2 (en) * 2000-03-30 2010-07-27 Kao Corporation Skin external agents and drugs
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SK288238B6 (sk) * 2001-01-12 2015-01-07 Fumapharm Ag Amidy kyseliny fumarovej
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
KR101153250B1 (ko) * 2003-08-12 2012-06-05 니폰 조키 세야쿠 가부시키가이샤 글리시리진 고농도 제제
US20050192243A1 (en) * 2003-10-28 2005-09-01 Savarese John J. Neuromuscular blocking agents and antagonists thereof
EP1965763B1 (en) * 2005-12-27 2019-11-06 Ramot at Tel Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
AU2007328210B2 (en) 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) * 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection

Also Published As

Publication number Publication date
EP2101772B1 (en) 2012-04-25
ATE554769T1 (de) 2012-05-15
AU2007328210A2 (en) 2011-06-09
US8148398B2 (en) 2012-04-03
US20080139482A1 (en) 2008-06-12
WO2008070121A1 (en) 2008-06-12
EP2101772A4 (en) 2010-12-01
JP2010511715A (ja) 2010-04-15
CA2671904A1 (en) 2008-06-12
CN101588803B (zh) 2013-03-20
AU2007328210B2 (en) 2012-11-22
CN101588803A (zh) 2009-11-25
AU2007328210A1 (en) 2008-06-12
EP2101772A1 (en) 2009-09-23
JP5213137B2 (ja) 2013-06-19

Similar Documents

Publication Publication Date Title
CA2671904C (en) Intermediate duration neuromuscular blocking agents and antagonists thereof
JP2010511715A5 (OSRAM)
Ruetsch et al. From cocaine to ropivacaine: the history of local anesthetic drugs
US20190247377A1 (en) Neosaxitoxin combination formulations for prolonged local anesthesia
Sanford et al. Pretreatment with sedative-hypnotics, but not with nondepolarizing muscle relaxants, attenuates alfentanil-induced muscle rigidity
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
Shukla et al. Comparative evaluation of haemodynamic effects and intubating conditions after the administration of org 9426 (rocuronium) and succinylcholine
Takahashi et al. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl
EP3019169A1 (en) Hydroxychloroquine for the treatment of cardiovascular disease
US20050192243A1 (en) Neuromuscular blocking agents and antagonists thereof
Erkola et al. Does Diazepam Pretreatment Prevent Succinylcholine-Induced Fasciculations?-A Double-Blind Comparison of Diazepam and Tubocurarine Pretreatments
Frishman et al. Ultra-short-acting β-adrenergic blockers
CN112939896B (zh) 一种双季铵化合物及其制备方法和用途
KR20190117318A (ko) 우수한 안정성을 갖는 데옥시콜린산 함유 주사제 조성물 및 이의 제조방법
Agoston et al. Evolution of vecuronium requirements for stable mechanical effect: comparison with or without previous succinylcholine administration
Heinonen et al. Bradycardia during antagonism of pancuronium-induced neuromuscular block
EP0429676A1 (en) Drug for improving brain function
UA146317U (uk) Лікарський засіб в парентеральній лікарській формі
Silver et al. Theodore J. Sanford, Jr., MD,* Matthew B. Weinger, MD,? N. Ty Smith, MD, $ James L. Benthuysen, MD, 8 Norman Head, BS, ll
JP2023545505A (ja) Ｎｍｂａ投与後の回復を制御および予測するための方法
de Jong et al. Neuromuscular blocking agents do not alter local anesthetic seizure thresholds
Winsor et al. Treatment of the cardiac arrhythmias
Patwardhan et al. Rare Adverse Drug Reactions to Injection Neostigmine–A Report of Three Cases
Smith et al. Cardiovascular effects of benzquinamide
CN105030782A (zh) 具有抗心律失常作用的河豚毒素复方制剂及其制备方法

Legal Events

Date Code Title Description
EEER Examination request